

INOVATYON




International OVARian cancer patients Trial with YONdelis

- **Study title:** Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with relapsed ovarian cancer progressing within 6-12 months of last platinum
- **Sponsor:** Mario Negri Institute, MaNGO group, Milan, Italy
- **Principal Investigator:** Nicoletta Colombo, European Oncology Institute, Milan, Italy



No. Participating sites: 162

No. Opened sites: 136




Sites to be opened

Germany	6
UK	5
Spain	4
Italy	3
The Netherlands	3
Belgium	2
Norway	1
Danmark	1
Austria	1
Finland	0
Switzerland	0

Enrollment by country

Total No. random: 342



1 pt every 2.6 days
about 11 pts per month

Target

1 pt every 2 days
about 15 pts per month

Enrollment expected vs. observed

